Cangrelor increases the magnitude of platelet inhibition and reduces interindividual variability in clopidogrel-pretreated subjects

BACKGROUND: Inadequate platelet inhibition despite aspirin and clopidogrel therapy during and after a percutaneous coronary intervention is associated with an impaired clinical outcome. Cangrelor, a direct and reversible P2Y(12) inhibitor that is currently in development, has the potential to achiev...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Bouman, H.J., van Werkum, J.W., Hackeng, C.M., Clappers, N., ten Berg, J.M.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Bohn Stafleu van Loghum 2009
Ämnen:
Original Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC2688017/
https://ncbi.nlm.nih.gov/pubmed/19484155
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk